LSTA
LSTA clinical trials: LISATA THERAPEUTICS, INC.
Every trial on ClinicalTrials.gov where LISATA THERAPEUTICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 17
- Trials linked
- 17
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
LSTA on the catalyst calendar · LSTA registry changes
- Primary completion Apr 5, 2026ActualPhase 2NCT05712356A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsLisata Therapeutics, Inc. · CholangiocarcinomaCompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2022ActualPhase 2NCT04614467A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular DysfunctionLisata Therapeutics, Inc. · Coronary Microvascular DysfunctionTerminatedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2035Sponsor estimatePhase 1/Phase 2NCT06592664Certepetide Phase 1b/2a Continuous Infusion Trial in mPDACLisata Therapeutics, Inc. · Pancreas CancerWithdrawnLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2023ActualPhase 1NCT04990427CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)Lisata Therapeutics, Inc. · Chronic Kidney DiseasesCompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2021Sponsor estimatePhase 1NCT04522817CLBS119 for Repair of COVID-19 Induced Pulmonary DamageLisata Therapeutics, Inc. · Covid-19WithdrawnLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 19, 2022ActualPhase 2NCT02501018Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)Lisata Therapeutics, Inc. · Critical Limb IschemiaCompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 19, 2020ActualPhase 1NCT03517176CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic CancerLisata Therapeutics, Inc. · Pancreatic CancerCompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2009ActualPhase 1NCT00014131Vaccine Therapy in Treating Patients With Kidney CancerLisata Therapeutics, Inc. · Kidney CancerTerminatedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2008ActualPhase 2NCT00300053ACT34-CMI -- Adult Autologous CD34+ CellsLisata Therapeutics, Inc. · Myocardial IschemiaCompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2019ActualPhase 2NCT02691247Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)Lisata Therapeutics, Inc. · Diabetes MellitusCompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2019ActualPhase 2NCT03508609Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery...Lisata Therapeutics, Inc. · Coronary Microvascular DysfunctionCompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2016ActualPhase 3NCT01875653Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic MelanomaLisata Therapeutics, Inc. · Stage IV MelanomaTerminatedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2011ActualPhase 2NCT00814593Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed...Lisata Therapeutics, Inc. · Brain and Central Nervous System TumorsWithdrawnLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2015ActualPhase 3NCT01508910Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With...Lisata Therapeutics, Inc. · Chronic Myocardial IschemiaCompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2010ActualNo phase registeredNCT00545610ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)Lisata Therapeutics, Inc. · Myocardial IschemiaCompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2014ActualPhase 2NCT01495364NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial InfarctionLisata Therapeutics, Inc. · ST Segment Elevation Myocardial InfarctionCompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2011ActualPhase 1/Phase 2NCT00012064Vaccine Therapy in Treating Patients With Stage IV or Recurrent MelanomaLisata Therapeutics, Inc. · Melanoma (Skin)CompletedLSTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner